ArticleThe Journal of pediatrics2019
Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.
Article in The Journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04971694 (A Retrospective Chart Review Evaluating the Impact of Steroid, Diuretic, and Fluid Use Practice Trends in Extreme Premature Infants At Risk for Bronchopulmonary Dysplasia), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective Chart Review Evaluating the Impact of Steroid, Diuretic, and Fluid Use Practice Trends in Extreme Premature Infants At Risk for Bronchopulmonary Dysplasia (BPD) At a Single Center Neonatal Intensive Care Unit
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial.The Journal of pediatrics · 2025Trial
- What is the role of diuretics in the prevention and management of bronchopulmonary dysplasia?Current treatment options in pediatrics · 2026Article
- Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants.Journal of clinical pharmacology · 2026Article
- Predicting pulmonary hypertension in infants with bronchopulmonary dysplasia.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Landscape of bronchopulmonary dysplasia: from mechanisms to management.Frontiers in pediatrics · 2026Article
- Beyond Bronchopulmonary Dysplasia: A Comprehensive Review of Chronic Lung Diseases in Neonates.Cureus · 2024Review
- Use of furosemide in preterm neonates with acute kidney injury is associated with increased mortality: results from the TINKER registry.Pediatric nephrology (Berlin, Germany) · 2024Article
- Diuretic drug utilization in neonates: a French prescription database analysis.Frontiers in pharmacology · 2024Article
- Clinical characteristics of bronchopulmonary dysplasia in very preterm infants.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Cardiopulmonary physiological effects of diuretic therapy in preterm infants with chronic pulmonary hypertension.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
- Nephrocalcinosis in very low birth weight infants: incidence, associated factors, and natural course.Pediatric nephrology (Berlin, Germany) · 2022Article
- Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants.Archives of disease in childhood. Fetal and neonatal edition · 2022Article
- Association between postmenstrual age and furosemide dosing practices in very preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2022Observational
- Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?Frontiers in pediatrics · 2022Review
- Effects of Antioxidants in Human Milk on Bronchopulmonary Dysplasia Prevention and Treatment: A Review.Frontiers in nutrition · 2022Review
- Diuretic therapy and acute kidney injury in preterm neonates and infants.Pediatric nephrology (Berlin, Germany) · 2021Article
- Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.Journal of perinatology : official journal of the California Perinatal Association · 2021Review
- Use of diuretics in the neonatal period.Pediatric nephrology (Berlin, Germany) · 2021Review
- Fluid balance in early postnatal life: Should we keep the babies dry to prevent bronchopulmonary dysplasia?Pediatric research · 2021Article
- Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants.Children (Basel, Switzerland) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD). STUDY
designThis retrospective cohort study included infants (2004-2015) born at 23-29 weeks gestational age and 501-1249 g birth weight. We compared the demographic and clinical characteristics of infants exposed and not exposed to furosemide between postnatal day 7 and 36 weeks postmenstrual age. We examined the association between furosemide exposure and 2 outcomes: BPD and BPD or death. We performed multivariable probit regression models that included demographic and clinical variables in addition to 2 instrumental variables: furosemide exposure by discharge year, and furosemide exposure by site.
resultsOf 37 693 included infants, 19 235 (51%) were exposed to furosemide; these infants were more premature and had higher respiratory support. Of 33 760 infants who survived to BPD evaluation, 15 954 (47%) had BPD. An increase in the proportion of furosemide exposure days by 10 percentage points was associated with a decrease in both the incidence of BPD (4.6 percentage points; P = .001), and BPD or death (3.7 percentage points; P = .01).
conclusionsMore days of furosemide exposure between postnatal day 7 and 36 weeks was associated with decreased risk of BPD and a combined outcome of BPD or death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.